CEO Sofia Heigis presented to Aktiespararna at Aktiedagen in Stockholm

September 19, 2023

On Tuesday, September 19, Sofia Heigis presented Oncopeptides at Aktiedagen in Stockholm, an event organized by Aktiespararna.

During her presentation, followed by a question and answer session, Sofia reviewed some current events including the CHMP’s decision to recommend an approval for Pepaxti for earlier lines as well as the same authority’s decision to recommend the withdrawal of one of Pepaxti’s main competing drugs. She also gave an update on where the company is in the process of rolling out Pepaxti in Europe, a brief update on the appeal process in the US and her view on Oncopeptides as an investment.

In the following Q&A session, Sofia tells viewers what she thinks will be different with her as a new CEO, upcoming milestones for the company in the short term, and delves into what differs in the pricing process between different countries.

The presentation is available in Swedish only, and can be viewed below, or via the link Aktiespararna recording (YouTube):